Feature

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv pl...

Share

In the MajesTEC-3 trial, a combination of teclistamab and daratumumab demonstrated significant efficacy for previously treated multiple myeloma patients, achieving an 83% risk reduction in disease progression or death compared to standard regimens. Dr. María-Victoria Mateos and co-investigator Dr. Ajay K. Nooka noted that this regimen may set a new standard of care, supporting broader applications in clinical settings. Teclistamab, already FDA-approved for relapsed cases, shows potential as an innovative treatment solution, despite safety concerns related to infection rates.

Original Source(s)

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

  • by Caroline Helwick

  • March 20, 2026

Related Content

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) was approved today for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical ...

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission